<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="pmc">brjcancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">9310249</article-id><article-id pub-id-type="pmc">2228044</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>High-dose mitoxantrone with peripheral blood progenitor cell rescue: toxicity, pharmacokinetics and implications for dosage and schedule.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ballestrero</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ferrando</surname><given-names>F.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Garuti</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Basta</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gonella</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Esposito</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Vannozzi</surname><given-names>M. O.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sorice</surname><given-names>G.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Friedman</surname><given-names>D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Puglisi</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Brema</surname><given-names>F.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mela</surname><given-names>G. S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sessarego</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Patrone</surname><given-names>F.</given-names></name></contrib></contrib-group><aff>Dipartimento di Medicina Interna, Universit&#x000c3;&#x000a0; di Genova, Genoa, Italy.</aff><pub-date pub-type="ppub"><year>1997</year></pub-date><volume>76</volume><issue>6</issue><fpage>797</fpage><lpage>804</lpage><abstract><p>The optimal use of mitoxantrone (NOV) in the high-dose range requires elucidation of its maximum tolerated dose with peripheral blood progenitor cell (PBPC) support and the time interval needed between drug administration and PBPC reinfusion in order to avoid graft toxicity. The aims of this study were: (1) to verify the feasibility and haematological toxicity of escalating NOV up to 90 mg m(-2) with PBPC support; and (2) to verify the safeness of a short (96 h) interval between NOV administration and PBPC reinfusion. Three cohorts of ten patients with breast cancer (BC) or non-Hodgkin's lymphoma (NHL) received escalating doses of NOV, 60, 75 and 90 mg m(-2) plus melphalan (L-PAM), 140-180 mg m(-2), with PBPC rescue 96 h after NOV. Haematological toxicity was evaluated daily (WHO criteria). NOV plasma pharmacokinetics was also evaluated, as well as NOV cytotoxicity against PBPCs. Haematological recovery was rapid and complete at each NOV dose level without statistically significant differences, and there were no major toxicities. NOV plasma concentrations at the time of PBPC reinfusion were below the toxicity threshold against haemopoietic progenitors. It is concluded that, when adequately supported with PBPCs, NOV can be escalated up to 90 mg m(-2) with acceptable haematological toxicity. PBPCs can be safely reinfused as early as 96 h after NOV administration.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00170-0113.tif" xlink:title="scanned-page" xlink:role="797" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00170-0114.tif" xlink:title="scanned-page" xlink:role="798" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00170-0115.tif" xlink:title="scanned-page" xlink:role="799" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00170-0116.tif" xlink:title="scanned-page" xlink:role="800" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00170-0117.tif" xlink:title="scanned-page" xlink:role="801" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00170-0118.tif" xlink:title="scanned-page" xlink:role="802" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00170-0119.tif" xlink:title="scanned-page" xlink:role="803" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00170-0120.tif" xlink:title="scanned-page" xlink:role="804" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

